Loading
RECIST is the rulebook for measuring whether tumours have grown or shrunk on scans.
RECIST, the Response Evaluation Criteria in Solid Tumors 1.1, is the rulebook trials use to decide from scans whether tumours have grown or shrunk. It sums the longest diameters of up to five target lesions and sorts patients into complete response, partial response, stable disease or progressive disease, with a new lesion always counting as progression. The iRECIST variant adjusts for pseudoprogression on immunotherapy. RECIST does not capture metabolic or ctDNA response, a gap behind ideas on clonal clearance as an endpoint and ctDNA futility gates. It depends on the CT (computed tomography) and MRI technologies, underpins Objective response rate (ORR), and features in ideas on AI-assisted central imaging reads and structured radiology reports.
Showing the technology this term belongs to: CT (computed tomography).
A drug that shrinks tumours or delays progression on scans has not necessarily been shown to help patients live longer or better. Patients and clinicians should ask what the endpoint was; regulators should insist on timely confirmatory trials; and trialists should validate surrogates before relying on them.
Almost every response rate and progression-free survival figure quoted on this site rests on RECIST. Knowing that a partial response means a 30% shrinkage of a few measured lesions, not a cure, helps read trial results honestly, and the criteria's limits with immunotherapy led to iRECIST for delayed and mixed responses.
Shares Partial response, Complete response, Objective response rate (ORR), Progression-free survival (PFS).
Shares Partial response, Progression, Complete response.
Shares Partial response, Surrogate endpoint validation: which stand-ins have earned trust, Objective response rate (ORR), Progression-free survival (PFS).
Shares Prasad: most surrogate endpoints in cancer trials correlate poorly with survival, Objective response rate (ORR), Progression-free survival (PFS).
Shares Kill combination arms early using circulating tumour DNA, before waiting for scans, Use a blood test at six weeks to decide whether to keep going.
Shares A regulatory endpoint for drugs that block spread, not tumours, Progressive disease and radiographic progression, Biopsy the one lesion that is growing while the others shrink.
Shares Duration of response (DoR) and disease control rate (DCR), Surrogate endpoint validation: which stand-ins have earned trust, Objective response rate (ORR).
Shares Surrogate endpoint validation: which stand-ins have earned trust, Objective response rate (ORR), Progression-free survival (PFS).